Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 3Completed 3Unknown 2Terminated 1

Sponsor Class

OTHER_GOV 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Refractory Solid Tumors 1Lung Neoplasms 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Hydralazine × Clear all
NCT00996060 2016-01-18

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

New Mexico Cancer Research Alliance

Phase 1 Completed
29 enrolled
Thoracic

Lung Neoplasms

NCT00404326 2006-11-28

Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer

National Institute of Cancerología

Phase 2 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00404508 2006-11-28

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

National Institute of Cancerología

Phase 2 Completed
15 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡